Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?

Yamanaka K, Chatterjee N, Hemann MT, Walker GC.

PLoS Genet. 2017 Aug 17;13(8):e1006842. doi: 10.1371/journal.pgen.1006842. eCollection 2017 Aug. No abstract available.

2.

Chronic treatment with cisplatin induces chemoresistance through the TIP60-mediated Fanconi anemia and homologous recombination repair pathways.

Su WP, Ho YC, Wu CK, Hsu SH, Shiu JL, Huang JC, Chang SB, Chiu WT, Hung JJ, Liu TL, Wu WS, Wu PY, Su WC, Chang JY, Liaw H.

Sci Rep. 2017 Jun 20;7(1):3879. doi: 10.1038/s41598-017-04223-5.

3.

Mechanisms of DNA damage, repair, and mutagenesis.

Chatterjee N, Walker GC.

Environ Mol Mutagen. 2017 Jun;58(5):235-263. doi: 10.1002/em.22087. Epub 2017 May 9. Review.

PMID:
28485537
4.

Chromatin Regulates Genome Targeting with Cisplatin.

Zacharioudakis E, Agarwal P, Bartoli A, Abell N, Kunalingam L, Bergoglio V, Xhemalce B, Miller KM, Rodriguez R.

Angew Chem Int Ed Engl. 2017 Jun 1;56(23):6483-6487. doi: 10.1002/anie.201701144. Epub 2017 May 5.

5.

Ancient genes establish stress-induced mutation as a hallmark of cancer.

Cisneros L, Bussey KJ, Orr AJ, Miočević M, Lineweaver CH, Davies P.

PLoS One. 2017 Apr 25;12(4):e0176258. doi: 10.1371/journal.pone.0176258. eCollection 2017.

6.

Comprehensive and quantitative mapping of RNA-protein interactions across a transcribed eukaryotic genome.

She R, Chakravarty AK, Layton CJ, Chircus LM, Andreasson JO, Damaraju N, McMahon PL, Buenrostro JD, Jarosz DF, Greenleaf WJ.

Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):3619-3624. doi: 10.1073/pnas.1618370114. Epub 2017 Mar 21.

7.

Mechanisms of Post-Replication DNA Repair.

Gao Y, Mutter-Rottmayer E, Zlatanou A, Vaziri C, Yang Y.

Genes (Basel). 2017 Feb 8;8(2). pii: E64. doi: 10.3390/genes8020064. Review.

8.

Translesion synthesis of O4-alkylthymidine lesions in human cells.

Wu J, Li L, Wang P, You C, Williams NL, Wang Y.

Nucleic Acids Res. 2016 Nov 2;44(19):9256-9265. Epub 2016 Jul 27.

9.

Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction.

Actis ML, Ambaye ND, Evison BJ, Shao Y, Vanarotti M, Inoue A, McDonald ET, Kikuchi S, Heath R, Hara K, Hashimoto H, Fujii N.

Bioorg Med Chem. 2016 Sep 15;24(18):4339-4346. doi: 10.1016/j.bmc.2016.07.026. Epub 2016 Jul 16.

10.

The Regulation of DNA Damage Tolerance by Ubiquitin and Ubiquitin-Like Modifiers.

Cipolla L, Maffia A, Bertoletti F, Sabbioneda S.

Front Genet. 2016 Jun 13;7:105. doi: 10.3389/fgene.2016.00105. eCollection 2016. Review. Erratum in: Front Genet. 2016 Sep 30;7:184.

11.

Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation.

Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT.

Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3892-900. doi: 10.1073/pnas.1600582113. Epub 2016 Jun 20.

12.

Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair.

Roy U, Schärer OD.

DNA Repair (Amst). 2016 Aug;44:33-41. doi: 10.1016/j.dnarep.2016.05.004. Epub 2016 May 13. Review.

13.

The structure and duplex context of DNA interstrand crosslinks affects the activity of DNA polymerase η.

Roy U, Mukherjee S, Sharma A, Frank EG, Schärer OD.

Nucleic Acids Res. 2016 Sep 6;44(15):7281-91. doi: 10.1093/nar/gkw485. Epub 2016 Jun 1.

14.

Multiple functional linear model for association analysis of RNA-seq with imaging.

Jiang J, Lin N, Guo S, Chen J, Xiong M.

Quant Biol. 2015 Jun;3(2):90-102. Epub 2015 Aug 15.

15.

The Polymerase Activity of Mammalian DNA Pol ζ Is Specifically Required for Cell and Embryonic Viability.

Lange SS, Tomida J, Boulware KS, Bhetawal S, Wood RD.

PLoS Genet. 2016 Jan 4;12(1):e1005759. doi: 10.1371/journal.pgen.1005759. eCollection 2016 Jan.

16.

Rev1 promotes replication through UV lesions in conjunction with DNA polymerases η, ι, and κ but not DNA polymerase ζ.

Yoon JH, Park J, Conde J, Wakamiya M, Prakash L, Prakash S.

Genes Dev. 2015 Dec 15;29(24):2588-602. doi: 10.1101/gad.272229.115.

17.

A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB.

Cancer Cell. 2015 Nov 9;28(5):623-637. doi: 10.1016/j.ccell.2015.09.009. Erratum in: Cancer Cell. 2015 Dec 14;28(6):831.

18.

Human REV3 DNA Polymerase Zeta Localizes to Mitochondria and Protects the Mitochondrial Genome.

Singh B, Li X, Owens KM, Vanniarajan A, Liang P, Singh KK.

PLoS One. 2015 Oct 13;10(10):e0140409. doi: 10.1371/journal.pone.0140409. eCollection 2015.

19.

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy.

Jo U, Kim H.

Mol Cells. 2015 Aug;38(8):669-76. doi: 10.14348/molcells.2015.0175. Epub 2015 Jul 21. Review.

20.

Incorporation of metabolic activation potentiates cyclophosphamide-induced DNA damage response in isogenic DT40 mutant cells.

Hashimoto K, Takeda S, Swenberg JA, Nakamura J.

Mutagenesis. 2015 Nov;30(6):821-8. doi: 10.1093/mutage/gev042. Epub 2015 Jun 17.

Supplemental Content

Support Center